2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Clinical Procedures, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, (CAR)-T Cell Therapies, Workforce, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Quality Improvement, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Measurable Residual Disease, ALL, CLL, LGL, Hodgkin Lymphoma, Research, Fundamental Science, AML, APL, Translational Research, MDS, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4324 Accurate detection of TP53 copy-neutral loss of heterozygosity using SNP backbone probes coupled with the cnacs algorithm

Bin Chen, Yani Lin, PhD2, Hong Zhang3, Long Chen4, Kun Ru5
1 Sino-US Diagnostics Lab, Tianjin, China
2 Sino-US Diagnostics Lab, Tianjin, China
3 Sino-US Diagnostics Lab, Tianjin, China
4 Sino-US Diagnostics Lab, Tianjin, China
5 Shandong Cancer Hospital and Institute, Shandong, China

Introduction

Copy-neutral loss of heterozygosity (cnLOH) represents a prevalent genomic alteration in myeloid neoplasms, with a striking enrichment in TP53-mutated AML and MDS. The combination of a pathogenic TP53 variant and TP53 cnLOH drives complete biallelic loss of TP53 function, translating to substantially inferior clinical outcomes among myeloid tumor patients. Clinically, TP53 cnLOH is routinely inferred based on the VAF of TP53 mutations, where a VAF threshold of ≥55% is applied to presume concomitant TP53 cnLOH. However, this VAF-based surrogate strategy exhibits imperfect diagnostic performance. Existing literature confirms that a proportion of cases with bona fide biallelic TP53 inactivation will be misclassified as monoallelic TP53 mutation carriers if relying solely on VAF measurement.

Methods

A total of 9,241 single-nucleotide polymorphism (SNP) loci with minor allele frequencies (MAFs) ranging from 0.2 to 0.5 in the Chinese population were selected, covering the entire human genome at an average interval of approximately 300 kilobases (Kb). Custom probes targeting these SNP loci were synthesized and integrated into a targeted next-generation sequencing (NGS) panel covering mutational hotspots across 302 hematological malignancy-related genes. Variant calling was performed using VarDict software, while the CNACS algorithm was deployed to quantify TP53 copy number (TP53-CN) and detect TP53 cnLOH events.

Results

Bone marrow and peripheral blood specimens from 20 healthy individuals were used to establish baseline SNP backbone reference values. Following NGS of myeloid neoplasm samples, the default parameters of CNACS were applied to calculate the B-allele frequency within the TP53 genomic interval (TP53-BAF) and TP53-CN. In samples without any TP53 aberrations, the theoretical TP53-BAF equals 0.5 and TP53-CN equals 2. Myeloid neoplasms frequently harbor segmental gains or deletions of chromosome 17p, which alter TP53-CN and concomitantly skew TP53-BAF values. Accordingly, a corrected CN-adjusted BAF (CN-BAF) was first calculated to account for BAF deviation solely attributable to TP53 copy number alterations. A greater deviation between observed TP53-BAF and theoretical CN-BAF (driven by cnLOH) was defined as a positive TP53 cnLOH status. We established a diagnostic cutoff where TP53 cnLOH was deemed positive when the difference between CN-BAF and TP53-BAF exceeded 0.1; this cutoff is validated for specimens with a tumor cell fraction ≥20%.

We performed targeted NGS on a cohort of 712 patients diagnosed with MDS or AML, and TP53 cnLOH status was determined using the above algorithmic workflow. Overall, 18 patients tested positive for TP53 cnLOH, including 11 AML cases and 7 MDS cases. Among these 18 individuals, 2 AML patients carried wild-type TP53, whereas the remaining 16 harbored pathogenic TP53 mutations consistent with biallelic TP53 inactivation. Within the 16 patients with confirmed biallelic TP53 inactivation, 14 exhibited TP53 mutation VAFs above 55% (median VAF, 86.9%; range, 56.6%–93.6%). Only 2 MDS patients presented TP53 VAFs below the 55% cutoff, with VAF values of 31.8% and 44.9%, respectively. Therefore, exclusive reliance on the VAF ≥55% threshold would yield a false-negative rate of 12.5% (2/16) for identifying biallelic TP53 inactivation in this AML/MDS cohort.

Six patients reached the overall survival (OS) endpoint defined as all-cause death, with a median OS of only 7.5 months (range, 1–13.5 months). Of note, one 57-year-old male patient with MDS carrying concurrent TP53 cnLOH and a TP53 mutation (VAF = 31.8%) succumbed to refractory thrombocytopenia complicated by intracranial hemorrhage just one month following diagnosis, with an OS of only 1 month.

Conclusions

We established a novel detection workflow combining a customized SNP backbone probe panel and the CNACS algorithm for robust identification of TP53 cnLOH. TP53 cnLOH positivity was identified in 2.5% (18/712) of patients with MDS or AML. Using a VAF cutoff of ≥55% as the sole diagnostic criterion resulted in a 12.5% false-negative rate for detecting biallelic TP53 inactivation. Patients with TP53 mutation concurrent with TP53 cnLOH exhibited a dismal median OS of only 7.5 months. Collectively, an integrated analytical strategy incorporating copy number and BAF data enables more accurate characterization of biallelic TP53 status, providing a critical biomarker for prognostic stratification in patients with myeloid neoplasms.

Bin Chen: No relevant conflicts of interest to declare.